Gemcitabine in the treatment of metastatic pancreatic cancer

References

• Bouffard DY, Laliberte J, Momparler RL. Kinetic studies on 2´,2´-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem. Pharmacol.45, 1857–1861 (1997).
   Google Scholar
• Allerheiligen S, Johnson R, Hatcher B et al. Gemcitabine pharmacokinetics are influenced by gender, body surface area (BSA), and duration of infusion. Proc. Ann. Meeting Am. Soc. Clin. Oncol.338, (1994) (Abstract 13).
   Google Scholar
• Westphal S, Kalthoff H. Apoptosis: targets in pancreatic cancer. Mol. Cancer2(6), 1–14 (2003).
   PubMedGoogle Scholar
• Ferreira CG, Span SW, Peters GF et al. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res.60, 7133–7141 (2000).
   PubMed Web of Science ®Google Scholar
• Chandler NM, Canete JJ, Callery MP. Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine. J. Gastrointest. Surg.8, 1072–1078 (2004).
   PubMedGoogle Scholar
• Ueno H, Kiyosawa K, Kaniwa N. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br. J. Cancer97, 145–151 (2007).
   PubMed Web of Science ®Google Scholar
• Burris HA III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J. Clin. Oncol.15, 2403–2413 (1997).
   PubMed Web of Science ®Google Scholar
• Carmichael J, Fink U, Russell RC et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer73(1), 101–105 (1996).
   PubMed Web of Science ®Google Scholar
• Casper ES, Green MR, Kelsen DP et al. Phase II trial of gemcitabine (2´,2´-difluoro 2´-deoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs12(1), 29–34 (1994).
   PubMed Web of Science ®Google Scholar
• Hochster HS. Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents. Int. J. Radiat. Oncol. Biol. Phys.56(Suppl.4), 24–30 (2003).
   PubMedGoogle Scholar
• Touroutoglou N, Gravel D, Raber MN et al. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann. Oncol.9(9), 1003–1008 (1998).
   PubMed Web of Science ®Google Scholar
• Tempero M, Plunkett W, Ruiz van Haperen V et al. Randomized Phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J. Clin. Oncol.21(18), 3402–3408 (2003).
   PubMed Web of Science ®Google Scholar
• Poplin E, Levy DE, Berlin J et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion (FDR) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). J. Clin. Oncol.24(Suppl.18), 4004 (2006).
   Google Scholar
• Ko AH, Dito E, Schillinger B et al. A Phase II study of gemcitabine (GEM) given at fixed-dose-rate (FDR) infusion, low-dose cisplatin (CDDP), and bevacizumab (BEV) for metastatic adenocarcinoma of the pancreas (PanCa): Update with completion of study accrual. J. Clin. Oncol.25(Suppl.18), 4548 (2007).
   Google Scholar
• Espinosa E, Feliu J, de Castro J et al. Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic carcinoma. J. Clin. Oncol.25(Suppl.18), 15013 (2007).
   Google Scholar
• Kim J, Im S, Park E et al. Phase II study of induction chemotherapy with fixed dose rate (FDR) gemcitabine and cisplatin followed by concurrent chemoradiation with capecitabine for locally advanced pancreatic cancer. J. Clin. Oncol.25(Suppl.18), 15122 (2007).
   Google Scholar
• Hidalgo M, Castellano D, Paz-Ares L et al. Phase I–II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J. Clin. Oncol.17(2), 585–592 (1999).
   PubMed Web of Science ®Google Scholar
• Oettle H, Arning M, Pelzer U et al. A Phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. Ann. Oncol.11(10), 1267–1272 (2000).
   PubMedGoogle Scholar
• Rauch DP, Maurer CA, Aebi S et al. Activity of gemcitabine and continous infusion fluorouracil in advanced pancreatic cancer. Oncology60(1), 43–48 (2001).
   PubMed Web of Science ®Google Scholar
• Louvet C, Andre T, Hammel P et al. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Ann. Oncol.12(5), 675–679 (2001).
   PubMedGoogle Scholar
• Barone C, Cassano A, Corsi DC et al. Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a Phase I-II study. Oncology64(2), 139–145 (2003).
   PubMed Web of Science ®Google Scholar
• Marantz A, Jovtis S, Almira E et al. Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer. Semin. Oncol.28(Suppl.10), 44–49 (2001).
   PubMedGoogle Scholar
• Correale P, Messinese S, Marsili S et al. A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid. Br. J. Cancer89(2), 239–242 (2003).
   PubMed Web of Science ®Google Scholar
• Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol.20(15), 3270–3275 (2002).
   PubMed Web of Science ®Google Scholar
• Di Constanzo F, Carlini P, Doni L et al. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomized Phase II trial of the Italien oncology group for clinical research (GOIRC). Br. J. Cancer93(2), 185–189 (2005).
   PubMedGoogle Scholar
• Riess H, Helm A, Niedergethmann M et al. A randomized, prospective, multicenter, Phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs gemcitabine alone in patients with advanced pancreatic cancer. 2005 ASCO Annual Meeting Proceedings. J. Clin. Oncol.23(S16), 4009 (2005).
   PubMedGoogle Scholar
• Cartwright TH, Cohn A, Varkey JA et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J. Clin. Oncol.20(1), 160–164 (2002).
   PubMed Web of Science ®Google Scholar
• Hess V, Salzberg M, Borner M et al. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a Phase I/II trial. J. Clin. Oncol.21(1), 66–68 (2003).
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Schull B, Ulrich-Pur H et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized Phase II trial. Ann. Oncol.14(1), 97–104 (2003).
   PubMed Web of Science ®Google Scholar
• Heinemann V, Hoehler T, Seipelt A et al. Capecitabine plus Oxaliplatin (CapOx) versus Capecitabine plus Gemcitabine (CapGem) versus Gemcitabine plus Oxaliplatin (GemOx): a randomized Phase II trial in advanced pancreatic cancer. J. Clin. Oncol.23(Suppl.16), 4030 (2005).
   Google Scholar
• Cunningham D, Chau I, Stocken D et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur. J. Cancer4 (2005). (Abstract PS11).
   Google Scholar
• Herrmann R, Bodoky G, Ruhstaller T et al. Gemcitabine (G) plus Capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized Phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). 2005 ASCO Ann. Meeting Proc. J. Clin. Oncol.23(Suppl.16), 4010 (2005).
   Google Scholar
• Ueno H, Okusaka T, Ikeda M et al. A Phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology69, 421–427 (2005).
   PubMed Web of Science ®Google Scholar
• Ueno H, Okusaka T, Ikeda M et al. An early Phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology68, 171–178 (2005).
   PubMed Web of Science ®Google Scholar
• Okusaka T, Funakoshi A, Furuse J et al. A late Phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother. Pharmacol.61, 615–621 (2008).
   PubMed Web of Science ®Google Scholar
• Kindler HL, Duganm W, Hochster H et al. Clinical outcome in patients (pts) with advanced pancreatic cancer treated with permetrexed/gemcitabine. Proc. Am. Soc. Clin. Oncol. (2002). (Abstract 499).
   PubMedGoogle Scholar
• Oettle H, Richards D, Ramanathan RK et al. A Phase III trial of permetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann. Oncol.16(10), 1639–1645 (2005).
   PubMed Web of Science ®Google Scholar
• Heinemann V, Wilke H, Mergenthaler HG et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann. Oncol.11(11), 1399–1403 (2000).
   PubMed Web of Science ®Google Scholar
• Brodowicz T, Wolfram RM, Kostler WJ et al. Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer. Anticancer Drugs11(8), 623–628 (2000).
   PubMed Web of Science ®Google Scholar
• Philip PA, Zalupski MM, Vaitkevicius VK et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer92(3), 569–577 (2001).
   PubMed Web of Science ®Google Scholar
• Cascinu S, Labianca R, Catalano V et al. Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann. Oncol.14(2), 205–208 (2003).
   PubMedGoogle Scholar
• Heinemann V, Quietzsch D, Gieseler F et al. A Phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. Proc. Am. Soc. Clin. Oncol.22(Suppl.) (2003). Abstract 1003).
   Google Scholar
• Colucci G, Giuliani F, Gebbia V et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized Phase III study of the Gruppo Oncologia dell´italia Meridionale. Cancer94(4), 902–910 (2002).
   PubMed Web of Science ®Google Scholar
• Alberts SR, Townley PM, Goldberg RM et al. Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) Phase I study. Ann. Oncol.13(4), 553–557 (2002).
   PubMed Web of Science ®Google Scholar
• Alberts SR, Townley PM, Goldberg RM et al. Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group Phase II study. Ann. Oncol.14(4), 580–585 (2003).
   PubMed Web of Science ®Google Scholar
• Louvet C, Andre T, Lledo G et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter Phase II study. J. Clin. Oncol.20(6), 1512–1518 (2002).
   PubMed Web of Science ®Google Scholar
• Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J. Clin. Oncol.23(15), 3509–3516 (2005).
   PubMed Web of Science ®Google Scholar
• Poplin E, Levy DE, Berlin J et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR] versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). 2006 ASCO Annual Meeting Proceedings. J. Clin. Oncol.24(Suppl.18), 4004 (2006).
   Google Scholar
• Louvet C, Hincke A, Labianca R et al. Increased survival using platinum analog combined with gemcitabine as compared to gemcitabine single agent in advanced pancreatic cancer (APC): pooled analysis of two randomized trials, the GERCOR/GISCAD Intergroup Study and a German multicenter Study. J. Clin. Oncol.24, 179s (2006).
   Google Scholar
• Heinemann V, Hinke A, Böck S, Labianca R, Louvet C. Gemcitabine-based combinations (gem+x) vs gemcitabine (gem) alone in the treatment of advanced pancreatic cancer: a meta-analysis of sixteen randomized trials. J. Clin. Oncol.25(Suppl.18), 4515 (2007).
   Google Scholar
• Rocha Lima CM, Savarese D, Bruckner H et al. Irinotecan plus gemcitabine induces both radiographic and CA 19–9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J. Clin. Oncol.20(5), 1182–1191 (2002).
   PubMed Web of Science ®Google Scholar
• Royce ME, Hoff PM, Dumas P et al. Phase I and pharmacokinetic study of exathecan mesylate (DX-8951f): a novel campethecin analog. J. Clin. Oncol.19, 1493–1500 (2001).
   PubMed Web of Science ®Google Scholar
• Sun FX, Tohgo A, Bouvet M et al. Efficacy of camptothecin analog DX 8951f (exathecan mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res.63, 80–85 (2003).
   PubMed Web of Science ®Google Scholar
• Rocha Lima CM, Green MR, Rotche R et al. Irinotecan plus gemcitabine results in survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol.22, 3776–3783 (2004).
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Letourneau R, Harker G et al. Randomized Phase III study of exathecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J. Clin. Oncol.24, 4441–4447 (2006).
   PubMed Web of Science ®Google Scholar
• Okada S, Sakata Y, Matsuno S et al. Phase II study of docetaxel in patients with metastatic pancreatic cancer:a Japanese cooperative study. Br. J. Cancer80, 1377–1379 (1999).
   Google Scholar
• Lenzi R, Yalcin S, Evans DB et al. Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest.20, 464–470 (2002).
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Mavroudis D, Tsavaris N et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a Phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann. Oncol.12(1), 101–103 (2001).
   PubMed Web of Science ®Google Scholar
• Ryan DP, Kulke MH, Fuchs CS et al. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer94(1), 97–103 (2002).
   PubMed Web of Science ®Google Scholar
• Shepard RC, Levy DE, Berlin JD et al. Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the Eastern Cooperative Oncology Group. Oncology66(4), 303–309 (2004).
   PubMedGoogle Scholar
• Des Guetz G, Chauvenet L, Paraiso D et al. Docetaxel (Do) and gemcitabine (Gem) in advanced pancreatic cancer (APC) patients (pts): a multicentre study. J. Clin. Oncol.25(Suppl.18), 15065 (2007).
   Google Scholar
• Lutz MP, Van Cutsem E, Wagener T et al. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized Phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J. Clin. Oncol.23, 9250–9256 (2005).
   PubMed Web of Science ®Google Scholar
• Fine RL, Fogelman DR, Schreibman S et al. GTX chemotherapy for metastatic pancreatic cancer. 2004 ASCO Ann. Meeting Proc. J. Clin. Oncol.22(Suppl.18), 380 (2004).
   Google Scholar
• Kozuch P, Grossbard ML, Barzdins A et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist6, 488–495 (2001).
   PubMed Web of Science ®Google Scholar
• Rachamalla R, Malamud S, Mathew S et al. Phase I dose-finding of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors. Anticancer Drugs15, 211–217 (2004).
   PubMedGoogle Scholar
• Goel A, Grossbard ML, Malamud S et al. Pooled efficacy analysis from a Phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. Anticancer Drugs18, 263–271 (2007).
   PubMedGoogle Scholar
• Reni M, Ferreri AJM, Pancci MG et al. Significant improvement of response rate and survival with cisplatin, epirubicin, 5-fluorouracil and gemcitabine (PEF-G regimen) in metastatic pancreatic cancer. Eur. J. Cancer35(Suppl.) (1999) (Abstract 149).
   Google Scholar
• Reni M, Cordio S, Milandri C et al. Gemcitabine versus cisplatin, epirubicin, fluororuacil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre Phase III trial. Lancet Oncol.6, 369–376 (2005).
   PubMed Web of Science ®Google Scholar
• Reni M, Cereda S, Passoni P et al. A randomized Phase II trial of PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) or PDXG (docetaxel) regimen in advanced pancreatic adenocarcinoma. J. Clin. Oncol.25(Suppl.18), 4628 (2007).
   PubMedGoogle Scholar
• Bramhall SR, Rosemurgy A, Brown PD et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol.19, 3447–3455 (2001).
   PubMed Web of Science ®Google Scholar
• Bramhall SR, Schulz J, Nemunaitis J et al. A double-blind placebo controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer87, 161–167 (2002).
   PubMed Web of Science ®Google Scholar
• Moore MJ, Hamm H, Dancey J et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12–9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a Phase III trial of the National Cancer Institute of Canada Clincial Trials Group. J. Clin. Oncol.21, 3296–3302 (2003).
   PubMed Web of Science ®Google Scholar
• Macdonald JS, McCoy S, Whitehead RP et al. A Phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest Oncology Group (SWOG 9924) study. Invest. New Drugs23, 485–487 (2005).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, van de Helde H, Karasek P et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol.22(8), 1430–1438 (2004).
   PubMed Web of Science ®Google Scholar
• Ozawa F, Friess H, Tempia-Caliera A et al. Growth factors and their receptors in pancreatic cancer. Terat. Carcinog. Mutagen21, 27–44 (2001).
   PubMedGoogle Scholar
• Xiong HQ, Rosenberg A, LoBuglio et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter Phase II trial. J. Clin. Oncol.22, 2610–2616 (2004).
   PubMed Web of Science ®Google Scholar
• Philip PA, Benedetti J, Fenoglio-Preiser C et al. Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study. J. Clin. Oncol.25(Suppl.18), 4059 (2007).
   Google Scholar
• Ng SS, Tsao MS, Nicklee T et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinom. Mol. Cancer Ther.1, 777–783 (2002).
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol.25(15), 1960–1966 (2007).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Verslype C, Grusenmeyer PA et al. Lessons learned in the management of advanced pancreatic cancer. J. Clin. Oncol.25(15), 1949–1952 (2007).
   PubMedGoogle Scholar
• Oettle H, Hilbig A. Does the addition of erlotinib to gemcitabine improve outcome in patients with advanced pancreatic cancer? Nat. Clin. Pract. Oncol.4(12), 686–687 (2007).
   PubMedGoogle Scholar
• Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol. Cancer2, 8 (2003).
   PubMedGoogle Scholar
• Ikeda N, Adachi M, Taki T et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br. J. Cancer79, 1553–1563 (1999).
   PubMed Web of Science ®Google Scholar
• Seo Y, Baba H, Fukuda T et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer88, 2239–2245 (2000).
   PubMed Web of Science ®Google Scholar
• Kindler HL, Friberg G, Singh DA et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol.23, 8033–8040 (2006).
   Google Scholar
• Kindler HL, Niedzwiecki D, Hollis D et al. A double blind, placebo controlled, randomized Phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). J. Clin. Oncol.25(Suppl.18), 4508 (2007).
   PubMedGoogle Scholar
• Kim GP, Oberg AL, Foster NR et al. Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma. J. Clin. Oncol.25(Suppl.18), 4553 (2007).
   Google Scholar
• Spano J, Chodkiewicz C, Maurel J et al. A randomized Phase II study of axitinib (AG-013736) and gemcitabine versus gemcitabine in advanced pancreatic cancer, preceded by a Phase I component. J. Clin. Oncol.25(Suppl.18), 4551 (2007).
   Google Scholar
• Hirano T, Shino Y, Saito T et al. Dominant negative MEKK1 inhibits survival of pancreatic cancer cells. Oncogene21, 5923–5928 (2002).
   PubMed Web of Science ®Google Scholar
• Wallace JA, Locker G, Nattam S et al. Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): a Phase II trial of the University of Chicago Phase II Consortium. J. Clin. Oncol.25(Suppl.18), 4608 (2007).
   Web of Science ®Google Scholar
• Ulrich-Pur H, Raderer M, Verena Kornek G et al. Irinotecan plus raltitrexed versus raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic carcinoma. Br. J. Cancer88, 1180–1184 (2003).
   PubMed Web of Science ®Google Scholar
• Tsavaris N, Kosmas C, Skopelitis H et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A Phase II study. Invest. New Drugs23, 369–375 (2005).
   PubMed Web of Science ®Google Scholar
• Reni M, Pasetto L, Aprile G et al. Raltitrexed-eloxantin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br. J. Cancer94, 785–791 (2006).
   PubMed Web of Science ®Google Scholar
• Demols A, Peeters M, Polus M et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a Phase II study. Br. J. Cancer94, 481–485 (2006).
   PubMed Web of Science ®Google Scholar
• Oettle H, Arnold D, Esser M et al. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs11, 635–638 (2000).
   PubMed Web of Science ®Google Scholar
• Burris HA III, Rivkin S, Reynolds R et al. Phase II trial of rubitecan in previously treated pancreatic cancer patients. Oncologist10, 183–190 (2005).
   PubMed Web of Science ®Google Scholar
• Mitry E, Ducreux M, Ould-Kaci M et al. Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a Phase II trial. Gastroenterol. Clin. Biol.30, 357–363 (2006).
   PubMedGoogle Scholar
• Riess H, Pelzer U, Stieler J et al. A randomized second line trial in patients with gemcitabine refractory advanced pancreatic cancer–CONKO-003. J. Clin. Oncol.25(Suppl.18), 4517 (2007).
   Google Scholar
• Oettle H, Pelzer U, Stieler J et al. Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) versus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO-003). J. Clin. Oncol.23(Suppl.16), 4031 (2005).
   PubMedGoogle Scholar
• Boeck S, Hinke A, Wilkowski R, Heinemann V. Importance of performance status for treatment outcome in advanced pancreatic cancer. World J. Gastroenterol.13(2), 224–227 (2007).
   PubMedGoogle Scholar
• Icli F, Akbulut H, Utkan G et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J. Surg. Oncol.95, 507–512 (2007).
   PubMed Web of Science ®Google Scholar
• Pelzer U, Hilbig A, Stieler J et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy (PROSPECT CONKO-004). J. Clin. Oncol.24(Suppl.18), 4110 (2006).
   Google Scholar
• Sugiyama E, Kaniwa N, Kim SR et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol.25, 32–42 (2007).
   PubMed Web of Science ®Google Scholar
• Agarwal B, Abu-Hamda E, Molke KL et al. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. Am. J. Gastroenterol.99, 844–850 (2004).
   PubMed Web of Science ®Google Scholar
• Ko A, Scott J, Tempero MA et al. Detection of circulating micrometastases by flow cytometry in patients with pancreatic carcinoma. Presented at: Lustgarten Pancreatic Cancer conference, San Francisco, CA, USA 25–26 June 2004 (Abstract 50).
   Google Scholar
• Hoffmann K, Kerner C, Wilfert W et al. Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients. World J. Gastroenterol.13(2), 257–263 (2007).
   PubMed Web of Science ®Google Scholar
• Shah AN, Summy JM, Zhang J et al. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. (2007) (In press).
   Google Scholar
• Ryther RC, Flynt AS, Phillips JA III, Patton JG. siRNA therapeutics: big potential from small RNAs. Gene Ther.12, 5–11 (2005).
   PubMed Web of Science ®Google Scholar
• Welsh SJ, Koh MY, Powis G. The hypoxic inducible stress response as a target for cancer drug discovery. Semin. Oncol.33, 486–497 (2006).
   PubMed Web of Science ®Google Scholar
• Petrulio CA, Kaufman HL. Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Rev. Vaccines5, 9–19 (2006).
   PubMed Web of Science ®Google Scholar
• Nava-Parada P, Emens LA. GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers. Curr. Opin. Mol. Ther.9(5), 490–497 (2007).
   PubMed Web of Science ®Google Scholar
• Evans T, Ramanathan RK, Yazji S et al. Final results from cohort 1 of a Phase II study of volociximab, an anti-α5β1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC). J. Clin. Oncol.25(Suppl.18), 4549 (2007).
   Google Scholar
• Nugent FW, Cunningham C, Barve MA et al. Phase II study of talabostat/gemcitabine in stage IV pancreatic cancer. J. Clin. Oncol.25(Suppl.18), 4616 (2007).
   PubMedGoogle Scholar
• Khong HAT, Dreisbach L, Kindler HL et al. A Phase II study of ARQ 501 in combination with gemcitabine in adult patients with treatment naive, unresectable pancreatic adenocarcinoma. J. Clin. Oncol.25(Suppl.18), 15017 (2007).
   Google Scholar